Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Necrotizing enterocolitis: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in necrotizing enterocolitis: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Sepsis diagnosed after randomisation: range 28 d to 60 d · preterm infants
Intramuscular vitamin K showed no clear difference in sepsis: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Mortality (all infants): 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in mortality (all infants): 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Bleeding complications: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in bleeding complications: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Intraventricular hemorrhage > Grade II: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in intraventricular hemorrhage > Grade II: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Bleeding complications: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in bleeding complications: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Sepsis: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in sepsis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Mortality (all infants): 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in mortality (all infants): 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Intraventricular hemorrhage > Grade II: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in intraventricular hemorrhage > Grade II: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Change in cardiac function: change (decline) from baseline in left ventricular strain · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Change in Ejection fraction (%) · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Improvements in quality of life measures · boys with DMD and left ventricular ejection fraction 45% or more
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found